Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Diabetic retinopathy, a leading cause of blindness in working-age adults, silently damages eyes through high blood sugar.

New AI-powered retinal cameras can detect diabetic eye disease in just seconds — even in clinics or pharmacies — allowing ...

What is laser photocoagulation? A laser procedure that seals leaking blood vessels to slow vision loss in wet age-related ...

Ireland has a serious problem with high blood pressure. Our rates are among the highest in the world, and we have a poor ...

New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer will benefit from five medicines that Pharmac will fund from 1 December 2025.

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

DelveInsight's KLKB1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

4D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market 4D-150, a treatment for wet age-related macular degeneration (wet AMD) ...